The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
T2 BIOSYSTEMS INC | COM | 89853L104 | 6,858 | 1,632,816 | SH | DFND | 0 | 1,632,816 | 0 | ||
T2 BIOSYSTEMS INC | COM | 89853L104 | 1,335 | 317,767 | SH | DFND | 2 | 0 | 317,767 | 0 | |
SERES THERAPEUTICS INC | COM | 81750R102 | 203,433 | 12,682,876 | SH | DFND | 2 | 0 | 12,682,876 | 0 | |
EDITAS MEDICINE INC | COM | 28106W103 | 40,203 | 1,674,435 | SH | DFND | 2 | 0 | 1,674,435 | 0 | |
SYROS PHARMACEUTICALS INC | COM | 87184Q107 | 47,169 | 3,204,437 | SH | DFND | 2 | 0 | 3,204,437 | 0 |